Pfizer Hemophilia is donating more than 35 million IUs of its recombinant factor IX therapy to the World Federation of Hemophilia (WFH) to help hemophilia B patients in underserved regions of the world.
"This donation has the potential to impact people living with hemophilia B in more than 40 countries worldwide," said Alain Weill, WFH president. "The WFH relies on these donations to advance our goal of improving and introducing treatment in developing countries where care might not otherwise be available. We are thankful for our continued work with companies like Pfizer, which has historically made some of the largest donations to our Humanitarian Aid program, which channels donations of life-saving treatment products to people with bleeding disorders who need them and supports our vision of Treatment for All."
"The product donation underscores our joint commitment to providing hemophilia medicines in developing countries and hemophilia care around the world," said Andrew Callos, Vice President, Commercial Development, Pfizer. "We understand that overall care has improved for people living with hemophilia, but significant disparities still exist, with about 75 per cent of people with bleeding disorders receiving inadequate treatment or no treatment at all. It is our hope that, by partnering with organizations like the WFH, Pfizer can help bridge the treatment gap and continue providing access to hemophilia medicines for patients who need them."
This donation and Pfizer's ongoing commitment will continue to strengthen the WFH's Global Alliance for Progress (GAP) Program and help provide those in need with valuable and life-saving medicines. In addition to this initiative, Pfizer is the exclusive sponsor of the WFH Twinning Program, a program that partners developing and developed patient organizations or treatment centres. WFH's latest 50th anniversary film, Changing Lives Through Twinning, will be released by the WFH in early November.
World Federation of Hemophilia